Details of the Drug Formulations

General Information of Drug (ID: DMX6OE3)

• Drug Name: Dabrafenib Drug Info
• Synonyms: 1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Approved	[1]

• Cross-matching ID:
  PubChem CID: 44462760
  ChEBI ID: CHEBI:75045
  CAS Number: 1195765-45-7
  TTD ID: D05ROI
  VARIDT ID: DR00164
  INTEDE ID: DR0403
  ACDINA ID: D00163

Full List of Drug Formulations Containing This Drug

Dabrafenib Mesylate eq 50mg base capsule

Company	Formulation ID	FDA Description
Novartis	F23952	Colloidal Silicon Dioxide; Magnesium Stearate; Microcrystalline Cellulose; Hypromellose; Red Iron Oxide (E172); Titanium Dioxide (E171)

Dabrafenib Mesylate eq 75mg base capsule

Company	Formulation ID	FDA Description
Novartis	F23953	Colloidal Silicon Dioxide; Magnesium Stearate; Microcrystalline Cellulose; Hypromellose; Red Iron Oxide (E172); Titanium Dioxide (E171)

Dabrafenib 50 mg capsule

Company	Formulation ID	FDA Description
GlaxoSmithKline; Novartis Pharmaceuticals Corporation	F05202	Magnesium stearate; Ferric oxide red; Titanium dioxide; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses

Dabrafenib 75 mg capsule

Company	Formulation ID	FDA Description
GlaxoSmithKline; Novartis Pharmaceuticals Corporation	F05203	Magnesium stearate; Ferric oxide red; Titanium dioxide; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.